Welcome to the Settlement website for the Clovis Securities Litigation (Medina, et al. v. Clovis Oncology, Inc., et al., Civil Action No. 1:15-cv-02546-RM-MEH), pending in the United States District Court for the District of Colorado (the “Action”).
The Court-appointed Lead Plaintiff, M.Arkin (1999) LTD and Arkin Communications LTD, has reached a settlement of this Action with defendants Clovis Oncology, Inc. ("Clovis"), Patrick J. Mahaffy, Erle T. Mast, Andrew Allen, and Gillian Ivers-Read for $142 million, with $25 million paid in cash and $117 million paid in shares of Clovis common stock (the “Settlement”). The Settlement resolves all claims in the Action.
Following a hearing on October 26, 2017, the Court entered a Judgment approving the Settlement as fair, reasonable and adequate, and entered an order approving Lead Counsel’s motion for attorneys’ fees and reimbursement of expenses.
If you are a member of the Settlement Class, your rights will be affected and you may be eligible for a payment from the Settlement. The Settlement Class consists of:
All persons and entities who or which (i) purchased or otherwise acquired Clovis common stock and/or (ii) purchased or otherwise acquired exchange traded call options on Clovis common stock and/or sold/wrote exchange traded put options on Clovis common stock, between May 31, 2014 and April 7, 2016, inclusive (the “Class Period”), and who were damaged thereby.
If you are a member of the Settlement Class, in order to be potentially eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked no later than December 11, 2017. Payments to eligible claimants will be made only after the completion of all claims processing. Please be patient, as this process will take some time to complete.
|December 11, 2017||Claim Filing Deadline. Claim Forms must be postmarked no later than December 11, 2017 to be eligible for a payment from the Settlement.|